Humana Inc (NYSE:HUM) Shares Bought by Aperio Group LLC

Share on StockTwits

Aperio Group LLC increased its position in Humana Inc (NYSE:HUM) by 1.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 149,782 shares of the insurance provider’s stock after purchasing an additional 2,467 shares during the quarter. Aperio Group LLC owned approximately 0.11% of Humana worth $50,704,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in HUM. FMR LLC lifted its holdings in shares of Humana by 12.7% during the 2nd quarter. FMR LLC now owns 12,212,514 shares of the insurance provider’s stock valued at $3,634,811,000 after purchasing an additional 1,374,030 shares in the last quarter. Glenmede Trust Co. NA lifted its holdings in shares of Humana by 153.7% during the 2nd quarter. Glenmede Trust Co. NA now owns 500,266 shares of the insurance provider’s stock valued at $148,895,000 after purchasing an additional 303,080 shares in the last quarter. Unigestion Holding SA acquired a new stake in Humana in the 2nd quarter valued at approximately $79,340,000. LFA Lugano Financial Advisors SA acquired a new stake in Humana in the 2nd quarter valued at approximately $204,000. Finally, Summit Trail Advisors LLC raised its position in Humana by 24,611.8% in the 1st quarter. Summit Trail Advisors LLC now owns 184,103 shares of the insurance provider’s stock valued at $184,000 after buying an additional 183,358 shares during the last quarter. Hedge funds and other institutional investors own 92.62% of the company’s stock.

HUM has been the topic of a number of recent research reports. Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $377.00 target price on the stock in a research report on Thursday, October 4th. Argus boosted their price target on Humana to $375.00 and gave the stock a “buy” rating in a research report on Tuesday, September 4th. Piper Jaffray Companies boosted their price target on Humana from $355.00 to $380.00 and gave the stock an “overweight” rating in a research report on Friday, August 24th. Barclays assumed coverage on Humana in a research report on Thursday, September 13th. They set an “overweight” rating and a $370.00 price target on the stock. Finally, SunTrust Banks boosted their target price on Humana to $380.00 and gave the stock a “hold” rating in a report on Wednesday, September 19th. Seven research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $352.30.

Shares of HUM stock traded down $0.64 on Friday, hitting $338.95. 780,088 shares of the company’s stock were exchanged, compared to its average volume of 655,197. Humana Inc has a 12 month low of $231.90 and a 12 month high of $355.88. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 0.47. The company has a market cap of $48.77 billion, a P/E ratio of 28.95, a P/E/G ratio of 1.73 and a beta of 1.03.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.29 by $0.29. Humana had a return on equity of 19.36% and a net margin of 2.70%. The business had revenue of $14.21 billion during the quarter, compared to analysts’ expectations of $13.97 billion. During the same quarter in the prior year, the firm earned $3.39 EPS. As a group, equities research analysts anticipate that Humana Inc will post 14.44 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, January 25th. Stockholders of record on Monday, December 31st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, December 28th. This represents a $2.00 annualized dividend and a dividend yield of 0.59%. Humana’s payout ratio is 17.08%.

In other news, CEO Bruce D. Broussard sold 18,000 shares of the stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $328.66, for a total value of $5,915,880.00. Following the completion of the sale, the chief executive officer now owns 71,085 shares of the company’s stock, valued at $23,362,796.10. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Elizabeth D. Bierbower sold 3,092 shares of the company’s stock in a transaction dated Thursday, August 16th. The shares were sold at an average price of $330.00, for a total value of $1,020,360.00. Following the sale, the insider now owns 14,289 shares in the company, valued at approximately $4,715,370. The disclosure for this sale can be found here. Corporate insiders own 0.60% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Humana Inc (NYSE:HUM) Shares Bought by Aperio Group LLC” was posted by BBNS and is owned by of BBNS. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://baseballnewssource.com/2018/11/10/aperio-group-llc-has-50-70-million-holdings-in-humana-inc-hum/2847490.html.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Read More: Stop Order Uses For Individual Investors

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.